Clinical Trial Investigators Cannot Promote A Drug Prior To Its Approval, FDA Asserts
This article was originally published in The Pink Sheet Daily
Executive Summary
An investigator for Ipsen Biopharm's anti-wrinkling product Dysport touts it as superior to Botox in women's magazines and on the "Today Show."
You may also be interested in...
Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.